Aspen Neuroscience announced positive 12-month data from its ASPIRO Phase 1/2a clinical trial showing continued safety, tolerability, and sustained clinical benefit in Parkinson's disease patients 1 2 Sasineprocel (ANPD001) is an autologous induced pluripotent stem cell (iPSC)-derived dopaminergic neuron precursor cell therapy that converts patients' own skin cells into neurons for brain implantation 2 5 All eight treated patients in the trial showed marked improvements in symptom control, motor function, and quality-of-life measures at one year 5 The therapy does not require immunosuppressive drugs or permanent implantable hardware, eliminating associated adverse events and drug-monitoring requirements 2 3 The company completed Cohort Three dosing in January 2026 and expanded its GMP manufacturing facility in San Diego 3 Aspen plans to advance sasineprocel to a Phase 3 pivotal trial later in 2026 2 In November 2025, Aspen raised $115 million in Series C financing t...
- Get link
- X
- Other Apps